摘要
目的探讨肿瘤转移抑制基因TIP30的表达与小细胞肺癌(SCLC)临床病理特征及预后的关系。方法采用免疫组织化学En Vision二步法检测54例SCLC组织和42例SCLC癌旁组织TIP30的表达情况。结果 TIP30在SCLC组织和癌旁组织中的阳性率分别为80.95%和46.29%,差异有统计学意义(P<0.05);TIP30的表达与患者性别、年龄和吸烟情况无关,与临床分期、淋巴结转移、复发和远处转移有关。54例SCLC患者的中位总生存期为15.4个月;TIP30阳性表达者为26.6个月,明显长于阴性表达者的13.5个月,两者差异有统计学意义(P<0.05)。单因素分析显示,临床分期、远处转移及TIP30与预后相关;多因素分析显示,仅TIP30与预后有关(P=0.030)。结论 TIP30可以作为一个预测SCLC患者术后复发、转移及预后的分子标记物。
Objective To explore the relationship between the expression of TIP30 and its clinic-pathologic characteristics and prognosis in small cell lung cancer（SCLC）.Methods The expression of TIP30 in 54 cases of SCLC tissues and 42 cases of para-cancerous tissues were examined by En Vision method.Results The positive rate of TIP30 was 80.95% and 46.29% in SCLC tissues and para-cancerous tissues with statistic significance（P0.05）.The expression of TIP30 protein were not correlated with gender,age and smoking condition,but correlated with clinical stage,lymph node metastasis,recurrence and distant metastasis.The median overall survival of 54 cases of SCLC was 15.4 months,and it of TIP30 positive expression cases was 26.6 months,higher than 13.5 months in negative expression cases（P0.05）.Univariate analysis showed clinical stage,distant metastasis and TIP30 influenced the survival of SCLC patients,while multivariate analysis showed TIP30 was the only factor related to the prognosis of SCLC patients（P=0.030）.Conclusion TIP30 may be used as a molecular marker to identify and predict the relapse,metastasis and prognosis of SCLC.
出处
《临床肿瘤学杂志》
CAS
2012年第3期211-214,共4页
Chinese Clinical Oncology
基金
黑龙江省教育厅面上项目资助(12521279)
